Literature DB >> 21083990

[Expression of interleukin-6 in rat model of doxorubicin-induced nephropathy].

Li-Min Wang1, Ying-Jiao Chi, Li-Na Wang, Lei Nie, Yan-Hong Zou, Ta-Na Zhao, Chun-Yu Li, Mei Chen, Ming-Xia Huo.   

Abstract

OBJECTIVE: The pathogenesis of minimal change nephrotic syndrome (MCNS) remains unclear. This study aimed to investigate the expression of interleukin-6 (IL-6) in rats with doxorubicin-induced nephropathy and its possible roles in the pathogenesis of MCNS.
METHODS: Eighty-three male Wistar rats were randomly assigned into a control group (n=32) and a nephropathy group (n=51). Nephropathy was induced by a single tail vein injection of doxorubicin (5 mg/kg). The control group was injected with normal saline. Twenty-four-hour urinary protein excretion was measured 7, 14, 28 and 42 days after doxorubicin injection. IL-6 expression in urine and renal tissues was determined using ELISA 7, 14, 28 and 42 days after doxorubicin injection.
RESULTS: The urinary protein excretion increased significantly in the nephropathy group 7, 14, 28 and 42 days after doxorubicin injection compared with that in the control group (P<0.01). IL-6 expression in urine and renal tissues increased significantly 7, 14, 28 and 42 days after doxorubicin injection compared with that in the control group (P<0.01). IL-6 expression in urine and renal tissues was positively correlated with 24-hour urinary protein excretion in the nephropathy group (r=0.794, P<0.01; r= 0.870, P<0.01). IL-6 expression in urine was positively correlated with that in renal tissues (r=0.739, P<0.01).
CONCLUSIONS: IL-6 expression in the urine and renal tissues is increased in MCNS rats. IL-6 might play an important role in the pathogenesis of MCNS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21083990

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  7 in total

Review 1.  The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies.

Authors:  Wagner de Fátima Pereira; Gustavo Eustáquio Alvim Brito-Melo; Fábio Tadeu Lourenço Guimarães; Thiago Guimarães Rosa Carvalho; Elvis Cueva Mateo; Ana Cristina Simões e Silva
Journal:  Inflamm Res       Date:  2014-01       Impact factor: 4.575

2.  Insulin resistance in children with primary nephrotic syndrome and normal renal function.

Authors:  Jiaping Jin; Bo Jin; Songming Huang; Yanggang Yuan; Guixia Ding; Huaying Bao; Ying Chen; Yuan Han; Fei Zhao; Aihua Zhang
Journal:  Pediatr Nephrol       Date:  2012-05-24       Impact factor: 3.714

Review 3.  The experimental model of nephrotic syndrome induced by Doxorubicin in rodents: an update.

Authors:  Wagner de Fátima Pereira; Gustavo Eustáquio A Brito-Melo; Cayo Antônio Soares de Almeida; Lázaro Lopes Moreira; Cleiton Willian Cordeiro; Thiago Guimarães Rosa Carvalho; Elvis Cueva Mateo; Ana Cristina Simões E Silva
Journal:  Inflamm Res       Date:  2015-03-19       Impact factor: 4.575

Review 4.  Pathogenesis of minimal change nephrotic syndrome: an immunological concept.

Authors:  Seong Heon Kim; Se Jin Park; Kyoung Hee Han; Andreas Kronbichler; Moin A Saleem; Jun Oh; Beom Jin Lim; Jae Il Shin
Journal:  Korean J Pediatr       Date:  2016-05-31

5.  Respiratory Syncytial Virus Aggravates Renal Injury through Cytokines and Direct Renal Injury.

Authors:  Songhui Zhai; Lijuan Hu; Lin Zhong; Yannan Guo; Liqun Dong; Ruizhen Jia; Zheng Wang
Journal:  Front Cell Infect Microbiol       Date:  2016-09-30       Impact factor: 5.293

6.  SARS-CoV-2 infection associated acute kidney injury in patients with pre-existing chronic renal disease: A report of two cases.

Authors:  Yiru Wang; Yongman Lv; Qingquan Liu
Journal:  Immun Inflamm Dis       Date:  2020-07-28

7.  Effect of Nardostachys jatamansi DC. on Apoptosis, Inflammation and Oxidative Stress Induced by Doxorubicin in Wistar Rats.

Authors:  Mhaveer Singh; Mohammad Ahmed Khan; Kamal Y T; Javed Ahmad; Usama A Fahmy; Sabna Kotta; Nabil A Alhakamy; Sayeed Ahmad
Journal:  Plants (Basel)       Date:  2020-11-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.